WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.453
Volume 15, Issue 1, 669-693. Research Article ISSN 2277–7105

SILENT PATCHES, LOUD SCIENCE: REVISITING ALOPECIA AREATA

***[1]Anshu Jha, [2]Anubhava Kumar Burnwall, [3]Sambrita Karmakar**

India.

Article Received on 27 Nov. 2025,
Article Revised on 17 Dec. 2025,
Article Published on 01 Jan. 2026,

https://doi.org/10.5281/zenodo.18094403

***Corresponding Author**

Anshu Jha

Gupta College of Technological Sciences, West Bengal, India.

How to cite this Article: *1Anshu Jha, 2Anubhava Kumar Burnwall, 3Sambrita Karmakar. (2026) SILENT PATCHES, LOUD SCIENCE: REVISITING ALOPECIA AREATA. "World Journal of Pharmaceutical Research, 15(1), 669–693.

ABSTRACT

Hairs have been of great significance since historical times adding beauty to the personality of people. People rely on natural ways to manage their hairs. With the advancement in medical sciences, hairs have been a key indicator of physical as well as mental health. The term *alopecia* refers to patchy, partial or total loss of hairs from any part of the body, commonly known as baldness and its various types. The general population doesn't understand the anatomy and physiology of hairs and hair health thoroughly and mistakenly relate hair loss to genetic and hereditary factors, often ignoring the other possible causes like nutritional deficiencies, systemic diseases, acute and chronic illnesses, lifestyle-related factors, psychological issues etc. With the rapid surge in concern towards the hair health among population has led to rise in the cosmetic market as well. The market has flooded with various hair cosmetics addressing variety of issues like porosity, hair thinning, hair loss, discoloration, receding hair line etc. People are widely accepting these products based on their advertisement, regardless of the clear knowledge of root cause of their hair problem and the success rate of the products often remain unclear. The rise in alopecia cases has made the research into all the underlying causes and the possible treatments inevitable. In this article, we aim to explore the pathophysiology of alopecia and present a comprehensive overview of available treatments, including allopathic, homeopathic, naturopathic, cosmeceutical, and ayurvedic approaches, along with recent advancements.

KEYWORDS: Janus Kinase (JAK) Inhibitors, Autoimmune Hair Loss, Alopecia Areata, Immunopathogenesis, Hair loss.

● INTRODUCTION

Nonscarring hair loss is the hallmark of *Alopecia areata* (AA), a common autoimmune dermatological condition that usually manifests as clearly defined areas of hair loss on the scalp, face, or body. Both sexes are equally affected by the disease, which can strike at any age. AA is one of the most common types of autoimmune hair loss worldwide, with an estimated lifetime risk of 1.7%.[1]

From a clinical perspective, the disease manifests in multiple patterns, ranging from focal patchy alopecia to more severe forms such as alopecia totalis (total scalp hair loss) and alopecia universalis (complete loss of body hair). Although AA is not physically debilitating or life-threatening, it significantly impacts psychosocial well-being, often leading to anxiety, depression, social withdrawal, and reduced quality of life, particularly in children and young adults.[2]

The diagnostic approach is primarily clinical, supported by dermoscopic features such as "exclamation mark" hairs, black dots, yellow dots, and short vellus hairs. In uncertain or atypical cases, histopathology may reveal peribulbar lymphocytic infiltration, often described as a “swarm of bees,” which is a hallmark of AA.[3] Investigations into autoimmune issues such as thyroid dysfunction, vitiligo, and atopic conditions are often warranted, given their established associations.[1]

Therapeutic strategies have traditionally included ayurvedic and allopathic approaches, but treatment responses are variable, and long-term disease control remains elusive for many. The recent emergence of Janus kinase (JAK) inhibitors, including tofacitinib, ruxolitinib, and baricitinib, has marked a change in AA management by directly targeting key inflammatory pathways. Clinical trials have demonstrated significant efficacy, particularly in moderate-to-severe cases, and baricitinib has become the first FDA-approved systemic treatment for severe AA.[4,5]

Ongoing research is focused on understanding the genetic basis of the disease, the role of microbiota, and the development of biomarkers for predicting treatment response and the

progression of diseases.[3] Advances in personalized medicine and immunomodulation hold promise for improved outcomes and quality of life for affected individuals.

This review aims to comprehensively explore the current understanding of *alopecia areata*, including its epidemiology, pathophysiology, clinical spectrum, psychological impact, diagnostic approach, available treatment modalities, and emerging research areas, with a special focus on recent advances in immunological research and their translational relevance in clinical practice.



Fig. 1: Anatomy of Human Skin.

HISTORY

Since Hippocrates, physicians have used the word "alopecia," which is derived from the Greek word "alopex," meaning "fur loss from the fox mange." The Latin term "*areata*" refers to a section of open ground, which is where the word "area" originates.

The Polish physician John Jonston (1603-1675) coined the term "*alopecia areata*" in his 1664 book "Medicina Practica." In the 1763 publication "Nosologia Methodica," French physician Sauvages de Lacroix (1706-1767) coined the term alopecia areata (AA).[6] *Alopecia* was categorized by Sauvages as areata- simplex, syphilitica, and volatilium.

Thomas Bateman (1778–1821), a student of renowned dermatologist Robert Willan, wrote "A Practical Synopsis Of Cutaneous Disease" in 1817, which contains the first clinical description of AA[7] as "Mostly circular bald patches," accompanied by "softer and lighter-coloured hair regrowth." He called it "porrigo decalvans," which means depilating scalp sickness, instead of AA, and suggested mace oil as a therapy.

Raymond Sabouraud (1864-1938), a French dermatologist and mycologist, compiled data from more than two hundred cases in 1929 and noted that 20% of the patients had favourable family histories and there were substantial correlations with illnesses that were later determined to be autoimmune.[8,9] The identification of peribulbar infiltrates by histological investigations, along with the beneficial impact of steroids, occurred in 1958. Antithyroid and anti-gastric parietal cell antibodies were shown to be more common in individuals with AA.

Recent genome-wide analyses have revealed genes like the UL16-binding protein gene, which draws cytotoxic cells to the hair follicles, which may be responsible for the immunologic alterations observed in AA.[10]

Causes

In AA, the body targets its anagen hair follicles, suppressing hair development, which is believed to be a systemic autoimmune disorder.[11] T cell lymphocytes, for instance, assemble around the affected follicles, resulting in inflammation and subsequently hair loss. In a healthy state, hair follicles are believed to be protected from the immune system by something known as immunological privilege.[12] There have been a few documented incidences of congenital AA in newborns,[13] which occurs in those cases where family members are affected.[11] Families with two or more affected members were studied, and strong evidence of a genetic connection with increased risk for AA was discovered. According to this study, these genes are most likely located in at least four different genomic areas.[15] Furthermore, rheumatoid arthritis, type 1 diabetes, and celiac disease are among the autoimmune disorders with which AA has genetic risk factors.[16] Symptoms of alopecia depend on the type of alopecia exhibited.

Some of the noteworthy features are as follows:

- Small bald patches on the scalp or other parts of the body
- Clusters of hair coming out in the shower or on a hairbrush
- Short, vellus hairs, yellow or black dots, and broken hair shafts
- Bitemporal thinning of the frontal and vertex scalp
- Hair breaking secondary to trauma or because of fragile hair.



Fig. 2 – Immune System Attacks Healthy Hair.

● CURRENT UNDERSTANDING OF ALOPECIA AREATA

Pathophysiology of AA

Briefly, pathophysiologic mechanisms of AA involve a multifactorial interaction between dysregulation of *immunity*, *environmental factors*, *genetic susceptibility*, chronic illnesses, and *poor lifestyle*. The most significant issue in AA is the identification of the **dysfunctional immune system** of hair follicle structures as foreign antigens and the consequent activation of an inflammatory response. The critical point in this regard is the loss of the immune privilege of the hair follicle because of several precipitating events like genetic predisposition, psychological stress, infections, and environmental factors.

Under normal conditions, during the anagen phase of hair growth, hair follicles are considered sites of immune privilege.[21] This is maintained by various mechanisms, such as reduced expression of major histocompatibility complex (MHC) class I and II molecules, expression of local immunosuppressive cytokines like transforming growth factor-beta (TGF-β), alpha-melanocyte-stimulating hormone (α-MSH), and interleukin-10 (IL-10), and expression of physical barriers to the entry of the immune cells.[22]

As a result of the violation of immune privilege, follicular antigens, otherwise sequestered from immune cells, become exposed.[23] which activates and triggers autoreactive CD8+ NKG2D+ cytotoxic T cells, which are found mainly around the *bulb* of the hair follicle. These T cells release pro-inflammatory cytokines, such as interleukin-15 (IL-15) and interferon-gamma (IFN-γ), which heighten the immune response and promote the recruitment of other immune cells, such as CD4+ T helper cells, dendritic cells, and natural killer (NK) cells.[24] IFN-γ induces upregulation of MHC class I and II molecules on follicular keratinocytes, hence making them more vulnerable to immune cells and inflammation.[25] The

inflammatory response results in an initial transition of the hair follicle from the anagen phase to the catagen or telogen phases, ultimately leading to hair loss.[26]

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway has been established as a central element in the pathophysiologic processes of AA. The binding of interferon-gamma (IFN-γ) and interleukin-15 (IL-15) to their respective receptors initiates the activation of the JAK-STAT pathway.[27] This results in the transcription of pro-inflammatory genes that enable the survival and proliferation of T cells. The efficacy of JAK inhibitors such as tofacitinib and ruxolitinib in inducing hair regrowth in AA patients reinforces the importance of this signaling pathway.[28]

Genetics also plays a role in influencing the pathophysiological processes of AA. Genome-wide association studies (GWAS) have identified numerous susceptible loci, particularly in the human leukocyte antigen (HLA) region, including HLA-DQB1 and HLA-DRB1, as well as other immune regulatory genes like CTLA4, IL2RA, and Eos.[29] These genes are hypothesized to play a role in the inappropriate activation and chronic persistence of autoreactive T lymphocytes.

Clarification of these pathophysiologic mechanisms has made it possible to develop novel therapeutic strategies that precisely target immune checkpoints and intracellular signal transduction pathways to promote disease control.[30]

● DIAGNOSIS

The medical identification of alopecia areata (AA) includes establishing patient background information, with a complete assessment of the scalp and hair-bearing area. It depends on clinical evaluation together with dermoscopic analysis and requires histopathological examination. A precise diagnosis at the beginning helps with immediate treatment and tracks potential systemic complications.[31]

The typical signs include clearly outlined circular or elliptical hairless areas, which start on the scalp, affecting eyebrows, eyelashes, the beard region, and body hair as well. The affected skin retains its normal smooth appearance because it shows no signs of inflammation or scaling.[31] The presence of "exclamation mark hairs" serves as a diagnostic marker for active AA because these broken hairs taper proximally while appearing at the edges of bald

areas.[32] Additionally, the presence of "cadaver hairs" appears as broken hairs that remain inside follicular openings.[33]

Dermoscopy (trichoscopy) serves as an essential non-invasive diagnostic method that improves clinical diagnosis. The dermoscopic indicators of AA show yellow dots (keratin- and sebum-filled follicular openings), black dots (pigmented broken hairs within follicles), tapering hairs, and short vellus hairs, which suggest the beginning of regrowth.[34] The clinical findings allow distinguishing AA from other hair loss conditions, including tinea capitis, trichotillomania, and androgenetic alopecia.[35]

For cases where scarring alopecia needs confirmation, a scalp biopsy becomes necessary.[36] The biopsy serves as a diagnostic tool to eliminate other possible conditions, including lupus erythematosus and lichen planopilaris.[38]

Diagnostic laboratory tests of thyroid function tests (T3, T4, TSH), anti-thyroid antibodies, ANA, and vitamin D levels[40] for AA are not standard practice, but doctors may order them when needed to check for related autoimmune disorders.

STANDARD TREATMENT PROCEDURES

After a thorough diagnosis, the treatment given to a patient includes individual or a combination of the four approaches: allopathic, homeopathic, naturopathic, and cosmetic treatments.

ALLOPATHIC TREATMENT FOR AA

CORTICOSTEROIDS

Due to their anti-inflammatory properties, corticosteroids have been the cornerstone of AA treatment since 1958 due to their simplicity of application, particularly in children, despite their varied efficacy from 60-75%.[43] They have been administered parenterally, orally, and topically. The effectiveness of using various topical steroid formulations varies. With a success rate ranging from 28.5% to 61%, fluocinolone acetonide 0.2% cream, 0.1% betamethasone valerate foam, 0.05% betamethasone dipropionate lotion, 0.1% halcinonide, and 0.05% clobetasol ointment/foam are popular.[42] It is advised to use one centimeter past the affected area. Even after receiving treatment, 37.5% of the responders experienced relapses.[42] Some temporary side effects, like Atrophy, telangiectasia, foliculitis, and hypopigmentation, are possible,[43] which can be overcome by avoiding superficial injections,

reducing volume and concentrations, and spacing out the injection sites, meaning using it every other day or five days a week.[43,44] When used near the eyebrows, cataracts and elevated intraocular pressure may develop.

Depending upon the affected part, the dosage should be decided as for the scalp, 10 mg/ml, and for the face and eyebrows, 2.5 mg/ml,[42] but not more than 20 mg.[47] Regrowth normally appears in 4 weeks, and if after 6 months there is no improvement, particularly in corticosteroid-resistant patients, probably because of less expression of the enzyme Thioredoxin reductase I, which activates the glucocorticoid receptor in the outer root sheath.

ANTHRALIN

It was the first option Thappa et al. utilized to treat patchy AA in kids under the age of ten.[44] In 75% of patchy AA patients and 25% of AT patients, anthralin was found to be beneficial.[43] The exact mechanism of action of Anthralin is unclear, but it is expected to work by producing free radicals, which have anti-inflammatory and immunosuppressive effects.[52] 0.5–1% cream is applied in conjunction with brief contact therapy. It is applied once a day for 20 to 30 minutes for two to three weeks. After that, the contact duration is progressively increased by five minutes each day for up to an hour, or until erythema and/or pruritus appear. This contact time is then maintained for three to six months. Prolonged inflammation, folliculitis, localized lymphadenopathy, and staining of hair, skin, and clothes are some side effects experienced.

MINOXIDIL

Regardless of its vascular effects, minoxidil promotes differentiation above the dermal papilla and proliferation at the base of the bulb to effectively promote hair regrowth. Minoxidil is used twice daily, and a 5% solution works better than a 2% solution.[49] Compared to elderly patients, younger patients respond better. It was used with anthralin or topical, or intralesional steroids for better outcomes.[50]

Some uncommon side effects include pruritus or dermatitis, which are less likely to occur with a foam formulation, and 3% of women reported having undesired facial hair.[49,51]



Fig. 3 & 4: 5- 2,4-Diamino-6-piperidinopyrimidine 3-oxide.

PROSTAGLANDIN ANALOGUES

Prostaglandin analogues, such as latanoprost and bimatoprost, are used to treat open-angle glaucoma, which can have the unfavourable side effect of hypertrichosis of the eyelashes and hair on the malar area.[53,54] These were attempted in eyelash AA but were found to be useless.

SULFASALAZINE

Sulfasalazine functions as an immunosuppressant and immunomodulator. It prevents the chemotaxis of inflammatory cells and the generation of cytokines and antibodies. Acceptable regrowth has been observed in 23% to 25.6% of AA patients.[56] In an uncontrolled open-label trial, Aghaei et al. discovered that 32% of AA patients experienced one or more adverse effects and that 27.3% of patients had complete hair regrowth and 40.9% had partial hair regrowth.[57] One can administer 0.5 g of sulfasalazine twice daily for a month, then 1 g for a month, and 1.5 g twice daily for a minimum of three months. Hepatotoxicity, haematological abnormalities, fever, rash, gastrointestinal distress, and headaches are among the possible side effects.

Finasteride: Another well-liked drug for alopecia is finasteride, which is particularly helpful for male pattern baldness in men. Dihydrotestosterone (DHT), a hormone that contributes to hair loss, is inhibited by finasteride.

Ketoconazole shampoo: Ketoconazole serves as an antifungal medicine that researchers believe reduces hair loss through its anti-inflammatory properties when used in specific shampoo products to improve scalp health.

MESOTHERAPY

Mesotherapy is now marketed as an AA treatment option. It is administered as intra- or subcutaneous injections that comprise enzymes, vitamins, minerals, homeopathic remedies, and pharmaceutical substances. Shulaia et al. observed that nicotinic acid, vitamin C, pentoxifiline, and trace elements administered over 28 weeks without any side effects resulted in hair growth in 21 patients.[58] On the other hand, two cases of patchy AA have been documented following mesotherapy with mesoglycan and homeopathic medicines.[59]

HOMEOPATHIC TREATMENT FOR ALOPECIA AREATA

Homeopathy usually centres on customized remedies based on the individual's general health and symptoms. Homeopathic treatments involve the use of *Thuja occidentalis*, Phosphorus, and Silica.

Thuja Occidentalis: Thuja is indicated in the history of vaccinations or suppressed skin conditions. It is also suitable for individuals with a history of warts or fungal infections. It stimulates the body's immune response and addresses the underlying imbalances.

Calcarea Carbonica: This remedy is suitable for individuals with a tendency towards obesity, excessive sweating, and sensitivity to cold temperatures. It is often prescribed for slow hair growth and brittle hair.[60]

Phosphorus: This remedy is often prescribed for excessive hair loss in spots. Individuals who may benefit tend to be sensitive and anxious, and fearful.[61]

Silica: Conditions characterized by brittle hair and sluggish hair growth are recommended for Silica. It is frequently advised for people who are prone to skin infections. It is believed to improve the strength and texture of hair.[62]

Arsenicum album and Graphites: This remedy is often recommended for individuals experiencing hair loss due to scalp conditions such as dandruff or psoriasis and eczema, where the skin condition is dry, rough, and cracked.[63,65]

Lycopodium clavatum: It is indicated for hair loss associated with hormonal imbalances, especially in individuals with liver or digestive issues. It works well for eczema and other scalp disorders that cause premature graying of the hair.[64]

NATUROPATHY TREATMENT FOR ALOPECIA AREATA

There are many evidence regarding natural options for alopecia which slows the progression of hair loss, encourage hair growth, and improve overall hair health. Those popular options available are caffeine, melatonin, and vitamin D.

Caffeine

An improvement in hair strength, a reduction in the amount of hair loss, and a slowing down of the balding process were noted as positive cosmetic outcomes[67] when it comes to patients experiencing hair loss due to an early end to the hair growth phase. Using a shampoo containing 10 mg/mL caffeine, telogen effluvium (where a large number of hairs enter into the resting phase) in females was evaluated.[67] More than half of the individuals showed a decrease in hair loss after 6 months of daily treatment on the scalp with 2 minutes of contact time.[67]

Melatonin

A naturally occurring hormone, melatonin, is released in reaction to darkness. It has been demonstrated to improve androgenetic alopecia without affecting the endogenous serum melatonin.[68] Although the exact mode of action is unknown, it may increase hair density and the growth phase of hair follicles.[69] A compounding pharmacy can add 0.05-0.1% melatonin to a customized topical medication to encourage hair growth.[68]

Vitamin D

Most of the research indicates a negative correlation between serum vitamin D levels and AA, androgenetic alopecia, and telogen effluvium. Researchers discovered that compared to the control group, those with alopecia areata had greater rates of vitamin D insufficiency and lower vitamin D levels.[71] Naturally, this suggests just correlation rather than causation. Many of the trials that treat alopecia with topical vitamin D have small sample sizes and conflicting results between studies.[72]

Herbal supplements: Various herbal products exist that claim they can support hair growth while preventing hair loss. Saw palmetto, together with ginseng and green tea extract, represents some of these examples. The supplements come in tablet and capsule formats.

Ayurvedic treatments: The Ayurvedic therapy in India provides herbal oils together with powders, and supplements for addressing hair loss. The products contain amla together with

bhringraj and brahmi, which are known for their hair-strengthening and nourishing properties.

Essential Oils: Certain essential oils, including lavender, along with peppermint and rosemary oils, possess properties that promote hair growth and improve scalp condition. Scalp massage applications and topical applications of diluted essential oils represent the two methods developers use to administer these substances.

Biotin supplements: Vitamin B7, also known as biotin, aims to strengthen hair follicles while promoting fresh hair development. People can find this supplement available for purchase at pharmacies and health stores.

COSMETIC TREATMENTS FOR AA

Cosmetic treatments for alopecia areata primarily focus on concealing the hair loss rather than treating the underlying cause. Some common cosmetic options are as follows:[73,74]

***Hair Fibers*:** The tiny, keratin-based fibers that stick to pre-existing hair to give it a fuller, thicker appearance. They come in a range of hues to complement different hair tones.

***Scalp Concealers*:** Products intended to disguise bald spots and thinning parts of the scalp are known as scalp concealers. They can offer transient covering and are frequently offered in spray or powder form.

***Wigs and Hairpieces*:** For those who are experiencing severe hair loss, wigs and hairpieces provide a complete answer. They are available in a variety of designs, hues, and materials, so customers can select one that looks natural.

***Scalp micropigmentation (SMP)*:** SMP is a cosmetic tattooing method in which hair follicles are simulated by applying pigment to the scalp. It can successfully conceal bald spots and provide the appearance of a neatly shaven head.

***Camouflaging Creams*:** By lessening the contrast between the scalp and surrounding hair, specialized creams and lotions that match the colour of the scalp can help hide bald spots.

Products for Volumizing and Thickening Hair: A few shampoos, conditioners, and styling products have chemicals that cover the hair shaft to give the appearance of thicker, fuller hair.

***Hair Transplant Surgery*:** A hair transplant becomes an option when hair loss reaches its most severe stages. Hair follicles from donor locations in the sides or back of the scalp are removed during the process and then transplanted into parts of the scalp that are balding or thinning.

RECENT ADVANCES IN TREATMENT FOR ALOPECIA AREATA

JAK Inhibitors: Tofacitinib and ruxolitinib are JAK inhibitors that show promising results for AA treatment, which target immune system components to reduce inflammation, which researchers believe triggers AA development.

***Platelet-Rich Plasma (PRP) Therapy*:** PRP therapy involves injecting concentrated platelets from the patient's blood directly into their scalp. Platelets contain growth factors that help activate hair follicles to promote hair growth.

***Stem Cell Therapy*:** It involves injecting stem cells directly into the scalp to regenerate hair follicle structures. The therapeutic approach demonstrates potential for AA treatment since it stimulates the growth of new hair follicles.

***Hair Transplantation*:** Follicular unit transplantation (FUT) and follicular unit extraction (FUE) represent modern hair transplantation methods that have seen substantial progress during the past several years. Doctors use these procedures to take hair follicles from scalp locations with sufficient hair density and transplant them into regions affected by AA.

***Laser Therapy*:** Research has explored the potential of low-level laser therapy (LLLT) for treating AA. The specific wavelengths produced by LLLT machines may promote hair growth through enhanced follicle cell activity and improved scalp blood circulation. The current scientific evidence suggests that low-level laser therapy (LLLT) functions through specific light wavelengths that activate hair follicle cells and improve scalp blood circulation to encourage hair growth.

***Nutritional and Lifestyle Interventions*:** Research indicates that AA might result from lifestyle conditions such as stress, along with nutritional deficiencies. Several therapy approaches should be integrated with dietary adjustments, along with stress management techniques and nutritional supplements, to manage the issue.

EXPLORING LONG-TERM OUTCOMES OF AA

Investigating its long-term outcomes involves examining both disease progression and its broader impact on patients' quality of life.

Remission Rates and Disease Progression

The clinical progression of AA remains highly unpredictable because patients experience either total natural hair restoration or sustained resistance to treatment. After diagnosis, about 30 to 50 percent of patients achieve complete hair recovery during the first year, yet relapse rates remain high.[75] The disease advances to more serious patterns in certain cases, whereby patients develop *alopecia totalis* (total scalp hair loss) along with *alopecia universalis* (total body hair loss), which show diminished therapeutic response and reduced possibilities for enduring recovery.[76]

Quality of Life Assessments

The psychological consequences of alopecia areata prove to be more intense than its physical symptoms. The condition substantially impacts emotional health, together with social interactions and self-perception. Key aspects include.

- **Emotional Well-Being:** The sight of hair loss causes visible anxiety and depression alongside feelings of helplessness among patients. The unpredictable behaviour of the condition makes these emotional responses worse.
- **Social Functioning:** The social stigma or discrimination that patients face causes them to avoid participating in social activities. The experience of bullying, along with peer rejection by children and adolescents, intensifies their psychological distress.
- **Self-Esteem and Body Image:** The personal connection people have with their hair causes its loss to damage their self-confidence. The degree of hair loss directly affects quality of life scores because people facing extensive or chronic hair loss report much lower scores than those with less severe conditions.
- **Psychological Support:** Psychological Support Corticosteroids, immunotherapies, and new JAK inhibitors all deal with the physical aspects of restoring or preventing loss of hair, but counselling and psycho-support groups aid patients in undergoing the emotional part of hair loss. Such methods as cognitive-behavioural therapy (CBT) and mindfulness interventions have proven to be the most successful in the reduction of anxiety and depression.

- **Social Advocacy:** Stigma can be fought by creating mass awareness, and the inclusion of the affected kids and teens can be advocated.
- **Cosmetic and Lifestyle Adaptations:** Wigs, head coverings, and makeup options provide practical solutions to improve confidence and social comfort.

Research Directions

Research that tracks patients through multiple years proves essential to understand disease development and remission patterns and evaluate the lasting psychological effects of AA.[80] Ongoing research into immune dysregulation, along with genetic susceptibility and environmental triggers, has identified multiple crucial pathways, including the JAK-STAT signalling cascade, which could become future therapeutic targets.[79] The integration of dermatological care with psychological and social support systems in patient-centered models shows positive results for both treatment compliance and quality of life (QoL) improvements.[81,82] The multidisciplinary approach demonstrates a contemporary direction toward personalized care, which tackles every aspect of AA's effects on patients' lives.

● ALOPECIA AREATA IN CHILDREN AND ADOLESCENTS

When children and adolescents develop AA, it normally appears in the form of bald patches on the head. In some cases, it may extend to eyebrows, eyelashes, and other body hair. Nearly 40% of its cases appear before patients reach their twenties. The disease affects patients through its physical signs and causes substantial harm to their emotional health, social life, and developmental progress.

There are certain difficulties in the diagnosis and treatment that are caused by the initial stages, like

- **Disease Presentation and Progression:** The severity of paediatric AA shows significant variation across different cases. The degree of hair loss among children ranges from moderate self-resolving cases to extreme cases, which include *alopecia totalis* or *alopecia universalis*. Children who develop chronic alopecia tend to face greater difficulties and experience increased chances of both persistent disease and recurrent episodes.
- **Social Challenges:** Children and adolescents experience bullying or peer teasing, which leads to social isolation and feelings of loneliness.
- **Parental Concerns:** Parents often experience feelings of powerlessness, together with guilt and worry regarding their child's health and subsequent life prospects.

- **Supportive Strategies:** Children and their families become better equipped to understand AA when they receive education that matches their developmental stage. Support groups exist both as physical gatherings and virtual communities, which help people feel connected while diminishing their sense of loneliness. Psychosocial interventions that include cognitive-behavioural therapy (CBT) help patients build resilience and boost their self-esteem.

- **FUTURE DIRECTIONS OF AA**

In the study of AA, researchers incorporate aspects of dermatology, immunology, genetics, and biotechnology to understand this autoimmune disease even better. They are in search of new biomarkers to unravel disease mechanisms and the discovery of new treatments. Through collaboration and openness, scientists will be able to leverage the strength of their knowledge and derive the tools to combat it. Below are key areas where collaborative research efforts are advancing the understanding of AA:

- **Genetics and Genomic Research**

  The modern genetics studies unite big groups of researchers who attempt to identify the hereditary causes that may provoke the development of this disease. **Genetic Susceptibility:** Genome-wide association studies (GWAS) have identified many genetic loci associated with AA. These areas tend to include immune system-related genes, most prominently the HLA (human leukocyte antigen) region. The dermatologists and geneticists have combined their knowledge and have developed better ways of identifying these loci.

- **Artificial Intelligence and Machine Learning in AA Research**

  The study of AA benefits from the increased usage of artificial intelligence (AI) together with machine learning (ML).

Diagnostic Tools: AI technologies assist medical professionals in detecting AA at its earliest stages by processing clinical scalp images, which reveal details that human observers may overlook. Dermatologists, together with data scientists, create AI-based diagnostic tools that help medical professionals evaluate disease severity and extent.

Predictive Modelling: The application of AI technology helps scientists forecast how AA will develop, together with its treatment outcomes. Machine learning algorithms examine

medical trial data alongside patient medical records to discover biomarkers or patterns that could predict therapy responses.

- **Multidisciplinary Collaboration in Clinical Trials**

New treatment testing for AA involves multiple research centers, along with hospitals and universities working together to recruit diverse patient populations. These collaborative approaches enable researchers to discover treatment plans that deliver both therapeutic benefits and safety across various population groups.

- **Global Collaboration:** Multicenter trials that involve researchers from different countries have led to a better understanding of the global prevalence of AA and have provided more robust evidence for the efficacy of treatments like JAK inhibitors and corticosteroids.

- **Patient-Centered Research:** Many multidisciplinary studies now involve patients in the design of clinical trials, ensuring that the research addresses real-world concerns and needs, which include patients' education about the disease. Healthcare providers, together with patient advocacy groups and researchers, deliver educational content about current treatment methods and new research discoveries. The partnership between patient advocacy groups and other organizations creates support networks for individuals who have AA while providing them with counselling services to prevent psychological dysregulation.

- **Personalized Medicine**

Patient receives personalized medical treatment by adjusting therapeutic strategies to match specific patient traits, which include their genetic makeup and biomarkers as well as their daily routine. The disease shows variability in patient responses, so a single treatment approach proves ineffective for all individuals. It includes:

- **Genetic-Based Personalized Medicine:** Identifying genetic variants associated with AA, such as HLA-DRB1 and HLA-DQB1 alleles, can help predict treatment response.
- **Biomarker-Based Personalized Medicine:** It includes **Inflammatory biomarkers** like IL-1β, TNF-α, and IFN-γ can help monitor disease activity and treatment response, and **Hair follicle biomarkers** like hair follicle stem cell markers can help predict treatment efficacy.

- **Lifestyle and Environmental Factor-Based Personalized Medicine:** It includes **Personalized Treatment Approaches** like tailored **Topical treatments** such as corticosteroids or minoxidil, based on individual skin types and hair loss patterns, **Systemic treatments** such as immunomodulators or biologics, based on individual disease severity, genetic profiles, and biomarker analysis and **Combination therapies:** such as pairing topical and systemic treatments, to optimize treatment outcomes.

CONCLUSION

Through awareness and public health strategies, along with the various treatment options available, we can prevent the occurrence of AA and enhance the lives of AA patients. The lack of knowledge among the population is the major cause of the stigma associated with the progression of the disease. The stigma associated can be reduced by **education and awareness campaigns, availability of treatment at the workplace, educational facilities, counselling services** for the patient and the family, **educating healthcare providers** as well, improving research and funding for new therapeutic developments. The **local communities** should be involved in creating awareness and providing other supportive services to the affected individuals.

ACKNOWLEDGEMENT

I would like to express my heartfelt gratitude to everyone who supported and encouraged me during the preparation of this review article. The collective insights, motivation, and constructive feedback from peers, mentors, and well-wishers have been invaluable in shaping this work.

I also acknowledge the contributions of researchers and clinicians whose dedicated efforts in the field of alopecia areata have laid the foundation for this review.

REFERENCES

1. Messenger AG, McKillop J, Farrant P, McDonagh AJG, Sladden M. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. *Br J Dermatol.*, 2012; 166(5): 916–26. doi:10.1111/j.1365-2133.2012.10955.x
2. Gilhar A, Etzioni A, Paus R. Alopecia areata. *N Engl J Med.*, 2012; 366(16): 1515–25. doi:10.1056/NEJMra1103442

3. Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. *Nature.*, 2010; 466(7302): 113–7. doi:10.1038/nature09114
4. Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. *J Clin Invest.*, 2016; 126(2): 543–52. doi:10.1172/JCI81260
5. King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. *N Engl J Med.*, 2022; 386(18): 1687–99. doi:10.1056/NEJMoa2110343
6. de Lacroix FB. Nosologia Methodica. Amsterdam: Fratr de Tournes; 1763. [Google Scholar]
7. Bateman T. A Practical Synopsis of Cutaneous Disease According to the Arrangement of Dr Willan. London: Longman, Hurst, Rees, Orme and Brown, Paterfoster-Row; 1817. [Google Scholar]
8. Sabouraud R. Pelades et Alopécies en Aires. Paris: Masson et cie Editeurs; 1929. [Google Scholar]
9. Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature, 2010; 466: 113–7. [PMC free article] [PubMed] [Google Scholar]
10. Zoe Diana Draelos (30 August 2007), Alopecia Areata Archived 8 December 2007 at the Wayback Machine. MedicineNet.com. Retrieved on, 2 December 2007.
11. Rajabi F, Drake L, Senna M, Rezaei N (2018). "Alopecia areata: A review of disease pathogenesis". British Journal of Dermatology, 179(5): 1033–1048.
12. Lenane P, Pope E, Krafchik B (February 2005). "Congenital alopecia areata". Journal of the American Academy of Dermatology (Case Reports. Review), 52(2 Suppl 1): 8–11.
13. Fukuyama M, Ito T, Ohyama M (January 2022). "Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines". The Journal of Dermatology, 49(1): 19–36.
14. Martinez-Mir A, Zlotogorski A, Gordon D, Petukhova L, Mo J, Gilliam TC, et al. (February 2007). "Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata". American Journal of Human Genetics, 80(2): 316–28.
15. Hordinsky M, Junqueira AL (June 2015). "Alopecia areata update". Seminars in Cutaneous Medicine and Surgery (Review), 34(2): 72–5.

16. Caproni M, Bonciolini V, D'Errico A, Antiga E, Fabbri P (2012). "Celiac disease and dermatologic manifestations: many skin clue to unfold gluten-sensitive enteropathy". Gastroenterology Research and Practice (Review), 2012; 1–12.
17. Tack GJ, Verbeek WH, Schreurs MW, Mulder CJ (April 2010). "The spectrum of celiac disease: epidemiology, clinical aspects and treatment". Nature Reviews. Gastroenterology & Hepatology (Review), 7(4): 204–13.
18. Duncan FJ, Silva KA, Johnson CJ, King BL, Szatkiewicz JP, Kamdar SP, et al. (February 2013). "Endogenous retinoids in the pathogenesis of alopecia areata". The Journal of Investigative Dermatology, 133(2): 334–43.
19. Gilhar A, Etzioni A, Paus R. Alopecia areata. *N Engl J Med*., 2012; 366(16): 1515-25.
20. Paus R, et al. The hair follicle and immune privilege. *J Investig Dermatol Symp Proc*., 2003; 8(2): 188-94.
21. Bertolini M, et al. Abolishment of immune privilege is key to the development of alopecia areata. *J Invest Dermatol*., 2014; 134(10) :2753-63.
22. Petukhova L, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. *Nature*., 2010; 466(7302): 113-7.
23. Xing L, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. *Nat Med*., 2014; 20(9): 1043-9.
24. Ito T, et al. Cytokines in the pathogenesis of alopecia areata. *Curr Drug Targets Inflamm Allergy*, 2005; 4(3): 285-90.
25. Gilhar A, Keren A, Shemer A, et al. Hair loss and hair follicle cycling in alopecia areata: A unifying hypothesis. *Autoimmun Rev*., 2016; 15(4): 382-90.
26. Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescents. *J Am Acad Dermatol*., 2018; 78(5): 1022-4. https://doi.org/10.1016/j.jaad.2017.12.041
27. Mackay-Wiggan J, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. *JCI Insight*., 2016; 1(15): e89790.
28. Betz RC, Petukhova L, et al. The genetics of autoimmune hair loss disorders. *Exp Dermatol*., 2015; 24(9): 720-6.
29. Christiano AM. New insights into the pathogenesis and therapy of alopecia areata. *Semin Cutan Med Surg*., 2015; 34(2): 53-6.
30. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol, 2010; 62(2): 177–188.

31. Inui S, Nakajima T, Itami S. Significance of dermoscopy in alopecia areata: analysis of 300 cases. Int J Dermatol., 2008; 47(7): 688–693.
32. Waśkiel-Burnat A, Rakowska A, Kurzeja M, Olszewska M, Rudnicka L. Trichoscopic markers of disease activity in alopecia areata. J Dermatol., 2021; 48(2): 186–191.
33. Tosti A, Duque-Estrada B. Dermoscopy in hair disorders. J Egypt Women Dermatol Soc., 2010; 7(1): 1–4.
34. Kibar M, Aktan Ş, Bilgin M, Ölmez U. Trichoscopic findings in differential diagnosis of patchy hair loss. Int J Trichology., 2020; 12(2): 78–82.
35. Dlova NC, Jordaan HF, Sayed R. Alopecia areata: Practical guidelines on diagnosis and management. South African Fam Pract., 2016; 58(6): 20–25.
36. Whiting DA. Histopathologic features of alopecia areata: A new look. Arch Dermatol., 2003; 139(12): 1555–1559.
37. Sperling L, Cowper SE. An Atlas of Hair Pathology with Clinical Correlations. 2nd ed. CRC Press, 2012.
38. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol, 2015; 8: 397–403.
39. Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A. Alopecia areata: clinical presentation, diagnosis, and unusual cases. Dermatol Ther., 2001; 14(4): 326–339. https://doi.org/10.1046/j.1529-8019.2001.014004326.x
40. Dlova NC, Jordaan HF, Sayed R. Alopecia areata: Practical guidelines on diagnosis and management. South African Fam Pract., 2016; 58(6): 20–25.
41. 22. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003; 49: 96-8.[Google Scholar]
42. AlKhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: Part II. Treatment. J Am Acad Dermatol.; 2010; 62: 191-202.[Google Scholar]
43. Thappa DM, Vijayikumar M. Alopecia areata. Indian J Dermatol Venereol Leprol, 2001; 67: 188.[Google Scholar]
44. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol., 2000; 42: 549-66. [Google Scholar]
45. Ito T. Advances in the management of alopecia areata. J Dermatol., 2012; 39: 11-7. [Google Scholar]
46. Shapiro J, Price VH. Hair regrowth. Therapeutic agents. Dermatol Clin 1998; 16: 341-56. [Google Scholar]

47. Sohn KC, Jang S, Choi DK, Lee YS, Yoon TJ, Jeon EK, et al. Effect of thioredoxin reductase 1 on glucocorticoid receptor activity in human outer root sheath cells. Biochem Biophys Res Commun, 2007; 356: 810-5. [Google Scholar]
48. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AB, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol., 2004; 50: 541-53. [Google Scholar]
49. Fiedler VC, Wendrow A, Szpunar GJ, Metzler C, DeVillez RL. Treatment resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. Arch Dermatol., 1990; 126: 756-9. [Google Scholar]
50. Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol., 2007; 57: 767-74. [Google Scholar]
51. Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A. Alopecia areata. Int J Dermatol., 2007; 46: 121-31. [Google Scholar]
52. Tosti A, Pazzaglia M, Voudouris S, Tosti G. Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol., 2004; 51: S149-50. [Google Scholar]
53. Coronel-Perez IM, Rodriguez-Rey EM, Camacho-Martinez FM. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol., 2010; 24: 481-5. [Google Scholar]
54. Vila TO, Camacho Martinez FM. Bimatoprost in the treatment of eyelash universalis alopecia areata. Int J Trichol., 2010; 2: 86-8. [Google Scholar]
55. Rashidi T, Mahd AA. Treatment of persistent alopecia areata with sulfasalazine. Int J Dermatol., 2008; 47: 850-2. [Google Scholar]
56. Aghaei S. An uncontrolled, open label study of sulfasalazine in severe alopecia areata. Indian J Dermatol Venereol Leprol., 2008; 74: 611-3.[Google Scholar]
57. Shulaia T, Kiladze N, Babilashvili I.Mesotherapy in treatment of alopecia areata. J Exp Clin Med., 2007; 1: 19-22. [Google Scholar]
58. Duque-Estrada B, Vincenzi C, Misciali C, Tosti A. Alopecia secondary to mesotherapy. J Am Acad Dermatol., 2009; 61: 707-9. [Google Scholar]
59. Chakraborty D, Ranganathan S. Homeopathy in alopecia areata: a retrospective study. Homeopath., 2014 Oct; 103(4): 249-54. doi: 10.1016/j.homp.2014.05.002. Epub 2014 Jul 5. PMID: 25268452.

60. Van Zuuren EJ, Fedorowicz Z, Schoones J. Homeopathy for alopecia areata. Cochrane Database Syst Rev., 2012 May 16; (5): CD007628. doi: 10.1002/14651858.CD007628.pub2. PMID: 22592709; PMCID: PMC6994703.
61. Thompson EA, Montgomery A, Douglas D, Reilly D. A pilot, randomized, double-blinded, placebo-controlled trial of individualized homeopathy for symptoms of estrogen withdrawal in breast-cancer survivors. J Altern Complement Med., 2005 Aug; 11(4): 633-41. doi: 10.1089/acm.2005.11.633. PMID: 16131286.
62. Rossi E, Bartoli P, Bianchi A, Da Fre M. Homeopathy in the treatment of postmenopausal symptoms of estrogen withdrawal syndrome: a comparative study in postmenopausal women. Homeopathy, 2009 Jan; 98(1): 17-21. doi: 10.1016/j.homp.2008.11.006. PMID: 19249983.
63. Witt CM, Ludtke R, Willich SN. Homeopathic treatment of patients with psoriasis--a prospective observational study with 2 years follow-up. J Eur Acad Dermatol Venereol., 2009 Feb; 23(2): 538-43. doi: 10.1111/j.1468-3083.2008.03063.x. Epub 2008 Aug 14. PMID: 18705656.
64. Shah R. Alopecia areata treated with homeopathy: a case series. Indian J Res Homoeopathy, 2017; 11: 124-130. doi: 10.4103/ijrh.ijrh_13_17.
65. Völker JM, Koch N, Becker M, Klenk A. Caffeine and Its Pharmacological Benefits in the Management of Androgenetic Alopecia: A Review. Skin Pharmacol Physiol., 2020; 33(3): 93-109. doi: 10.1159/000508228. Epub 2020 Jun 29. PMID: 32599587.
66. Sisto T, Bussoletti C, Celleno L. Role of a caffeine shampoo in cosmetic management of telogen effluvium. J Appl Cosmetol., 2013; 31: 139–45.
67. Fischer TW, Trüeb RM, Hänggi G, Innocenti M, Elsner P. Topical melatonin for the treatment of androgenetic alopecia. Int J Trichology, 2012 Oct; 4(4): 236-45. DOI: 10.4103/0974-7753.111199. PMID: 23766606; PMCID: PMC3681103.
68. Fischer TW, Burmeister G, Schmidt HW, Elsner P. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol., 2004 Feb; 150(2): 341-5. DOI: 10.1111/j.1365-2133.2004.05685.x. PMID: 14996107.
69. Xie Z, Komuves L, Yu Q-C, Elalieh H, Ng DC, Leary C, et al. Lack of the vitamin D receptor is associated with reduced epidermal differentiation and hair follicle growth. J Invest Dermatol., 2002; 118: 11–16.
70. Tsai T-Y, Huang Y-C. Vitamin D deficiency in patients with alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol., 2018; 78: 207–209.

71. Hosking AM, Juhasz M, Atanaskova Mesinkovska N. Complementary and Alternative Treatments for Alopecia: A Comprehensive Review. Skin Appendage Disord, 2019 Feb; 5(2): 72-89. DOI: 10.1159/000492035. Epub 2018 Aug 21. PMID: 30815439; PMCID: PMC6388561.
72. Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol., 2006; 20(9): 1055-1060. doi:10.1111/j.1468-3083.2006.01583.x
73. Harries MJ, Sun J, Paus R, King LE Jr. Management of alopecia areata. BMJ., 2010; 341: c3671. doi:10.1136/bmj.c3671
74. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol., 2015; 8: 397–403.
75. Cranwell WC, Lai VWY, Photiou L, Meah N, Wall D, Rathnayake D, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol., 2019; 60(2): 163–170.
76. Messenger AG, McKillop J, Farrant P, McDonagh AJG, Sladden M. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol., 2012; 166(5): 916–926.
77. Petukhova L, Christiano AM. The genetic architecture of alopecia areata. J Investig Dermatol Symp Proc., 2013; 16(1): S16–S22.
78. Petukhova L, Christiano AM. The genetic architecture of alopecia areata. J Investig Dermatol Symp Proc., 2013; 16(1): S16–S22.
79. Lee S, Lee H, Lee CH, Lee WS. Comorbidities in alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol., 2019; 80(2): 466–477.e16.
80. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol., 1996; 107(5): 707–713.
81. Hunt N, McHale S. The psychological impact of alopecia. BMJ., 2005; 331(7522): 951–953.
82. Bhat YJ, Latif I, Hassan I, Sheikh G. Vitamin D level in alopecia areata. Indian J Dermatol., 2017; 62(4): 407.
83. Kil MS, Kim CW, Kim SS. Analysis of serum zinc and copper concentrations in hair loss. Ann Dermatol., 2013; 25(4): 405–409.

84. Willemsen R, Haentjens P, Roseeuw D. Hypnotherapy for alopecia areata: a review. J Eur Acad Dermatol Venereol., 2010; 24(1): 17–22.
85. Hordinsky M, Ericson M. Autoimmunity: Alopecia areata. J Investig Dermatol Symp Proc., 2004; 9(1): 73–78.
86. Nita M, Grzybowski A. The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxid Med Cell Longev., 2016; 2016: 3164734.
87. Ryu HS, Park YM, Park SH, Lee JR, Lee YW. Association of environmental factors and use of cosmetics with allergic contact dermatitis in patients with hair loss. Ann Dermatol., 2019; 31(2): 181–186.